AUTHORS
Erin Mulvey, MD, Yumeng Zhang, MD2, Amir Ali, PharmD, BCOP3, Tara Graff, DO, MS4, Pallawi Torka5, Vardhaman Patel, PhD6, Monika Jun, MPH7, Abualbishr Alshreef, PhD, MSc, MPH8, Anthony Wang, PhD, MPH9, Tychell Branchcomb, PharmD10, Maithili Deshpande11, Lynn Huynh, PhD12, Angela Lax13, Mei Sheng Duh, ScD, MPH14, Talal Hilal, MD15, Muhamad Alhaj Moustafa, MD, MS16, Zahra Mahmoudjafari, PharmD, BCOP17, Daniel DeAvila Jr, M.S.18, Adrienne N. Nedved, PharmD, MPA19, Kanishka Uttam Chandani20, Javier L. Munoz, MD, MBA21, Roua Arian22, Peggy Graham23, Andrew Ip, MD, MS24, Yucai Wang, MD, PhD25
AFFILIATIONS
1 Weill Cornell Medicine, New York, New York, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 USC Norris Comprehensive Cancer Center & Hospital, Los Angeles, California, United States
4 Mission Cancer Blood/UIHSMG, Des Moines, Iowa, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Genmab US, Inc., Plainsboro, New Jersey, United States
7 Genmab US, Inc., Plainsboro, New Jersey, United States
8 AbbVie, Inc., Chicago, Illinois, United States
9 AbbVie, Inc., Chicago, Illinois, United States
10 Genmab US, Inc., Plainsboro, New Jersey, United States
11 Genmab US, Inc., Plainsboro, New Jersey, United States
12 Analysis Group, Inc., Boston, Massachusetts, United States
13 Analysis Group, Inc., Denver, Colorado, United States
14 Analysis Group, Inc., Boston, Massachusetts, United States
15 Mayo Clinic, Phoenix, Arizona, United States
16 Mayo Clinic, Jacksonville, Florida, United States
17 University of Kansas Cancer Center, Kansas City, Kansas, United States
18 Moffitt Cancer Center, Tampa, Florida, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Phoenix, Arizona, United States
21 Mayo Clinic, Phoenix, Arizona, United States
22 Mayo Clinic, Jacksonville, Florida, United States
23 Mission Cancer Blood/UIHSMG, Des Moines, Iowa, United States
24 John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, United States
25 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Introduction:
Epcoritamab (epcor) is a subcutaneous CD3xCD20 bispecific antibody approved for R/R DLBCL in the 3L+ setting. The pivotal EPCORE NHL-1 trial demonstrated deep, durable responses and manageable safety in heavily pretreated patients, roughly one-third of whom had prior CAR T-cell therapy (CAR T). Real-world populations are more heterogeneous than trial enrollees, with higher rates of refractory disease, poor performance status, and other adverse prognostic features. These differences may affect both response rates and response durability and should be considered when interpreting real-world outcomes relative to clinical trial findings. This analysis characterized real-world response rates and durability of response with epcor and benchmarked response outcomes against EPCORE NHL-1 in a target trial-emulated, weighted cohort.
Methods:
Real-EPCOR is an ongoing multicenter retrospective chart review study of adults with R/R DLBCL who initiated epcor in 3L+ setting on/after May 19, 2023, at academic and community oncology centers in the US.
Response was determined by the treating physician using imaging and/or clinical assessment. Best documented real-world overall response rate (rwORR) and real-world complete response rate (rwCRR) of any duration during treatment were summarized for all response-evaluable patients (≥1 assessment during epcor or died from progression before assessment) who received ≥1 dose of epcor. Duration of response (DOR) and duration of complete response (DOCR) were estimated from time of first response/CR until progression or death using Kaplan-Meier method. Patients were censored at the date of last clinical assessment or the initiation of the subsequent line of therapy, whichever occurred first.
The pre-specified primary analysis was focused on the target trial emulation cohort, using a propensity score weighting approach to align Real-EPCOR patients with key EPCORE NHL-1 eligibility criteria and baseline characteristics, benchmarking real-world outcomes directly against the pivotal trial.
Results:
The overall cohort included 132 patients who initiated epcor in 3L+. Median age was 68.6 (range 25.2-86.8) years, 68.9% were male. Median number of prior lines of therapy was 3 (range 2-11); at the time of initiating epcor, 57.9% had primary refractory disease, 65.9% had prior CAR T, 27.3% had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≥2, 66.7% had International Prognostic Index (IPI) score ≥3, 85.6% had Ann Arbor stage III-IV disease, and 22.7% had double-hit/triple-hit disease.
rwORR/rwCRR (95% CI) were 37.9% (29.6-46.7)/22.7% (15.9-30.8) among all patients, and 54.3% (43.6-64.8)/32.6% (23.2-43.2) among response-evaluable patients (n=92). Among patients with CR/PR (n=50; median follow-up, 13.5 months), median DOR was not reached (NR). The proportion of patients who maintained response was 82.3% at 6 months and 68.4% at 12 months. Among patients with CR (n=30; median follow-up, 17.5 months), median DOCR was NR, and the 6- and 12-month DOCR rates were both 95.8%.
In the pre-specified primary analysis, after applying key trial criteria, the target trial emulation cohort included 72 patients. Median age was 68.6 years (range 25.2-86.8); 60.3% had primary refractory disease, 75.0% had prior CAR T, 20.8% had ECOG PS=2, 66.7% had IPI score ≥3, and 83.3% had Ann Arbor stage III-IV disease. After weighting, key characteristics were similar between the real-world and trial cohorts; however, the proportion of patients with prior CAR T remained higher in the real-world cohort. Weighted rwORR/rwCRR (95% CI) were 43.5% (25.1-63.8)/25.9% (10.6-50.9) among all patients and 60.2% (36.3-80.1)/35.9% (15.1-63.8) among response-evaluable patients.
Conclusion:
In the pre-specified primary analysis, real-world effectiveness of epcor in patients with R/R DLBCL in 3L+ setting was consistent with EPCORE NHL-1 among patients in the target trial emulation cohort. Epcor’s effectiveness was also demonstrated in the overall cohort, with patients achieving durable complete responses despite a high prevalence of adverse prognostic features and clinically complex disease characteristics, providing evidence that epcor’s trial-demonstrated efficacy translates into routine US clinical practice, even in heavily pretreated populations.
DISCLOSURES
Erin Mulvey, MD: Lymphoma Research Foundation - Research Funding; Ipsen - Research Funding; Genentech - Research Funding; BeOne - Research Funding; National Institutes of Health (NIH) - Research Funding; BMS - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); IDEOlogy - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Curio Science - Consultancy (Includes expert testimony); MD Education - Consultancy (Includes expert testimony); Dava Oncology - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Curio - Consultancy (Includes expert testimony); Ipsen - Consultancy (Includes expert testimony)